+1 (786) 916 6163 info@akcellbio.com

Order number AK1601-S 100 assays

The AKCELL JAK2 AK™PCR Mutation Screen Kit is designed to screen for mutations on the JAK2 gene in genomic DNA, commonly associated with polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). JAK2 Mutations and Cancer

Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.g. interferon receptors), the GM-CSF receptor family (IL-3R, IL-5R and GM-CSF-R), the gp130 receptor family (e.g., IL-6R), and the single chain receptors (e.g. Epo-R, Tpo-R, GH-R, PRL-R). JAK2 signaling is activated downstream from the prolactin receptor.[1]

JAK2 gene fusions with the TEL(ETV6) (TEL-JAK2) and PCM1 genes have been found in leukemia patients.[5][6] Jak – 2 kinase mutations were found to have a high correlation with abnormal heart defects in those of Southeast Asian descent carrying the PYFA gene.[2][3] Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and myelofibrosis as well as other myeloproliferative disorders.[4] This mutation (V617F), a change of valine to phenylalanine at the 617 position, appears to render hematopoietic cells more sensitive to growth factors such as erythropoietin and thrombopoietin, because the receptors for these growth factors require JAK2 for signal transduction.

Equipment Compatible with ABI 7500 Real-Time Systems or equivalent. Intended Use AKCELL’s JAK2 mutation screen reagents are provided for research use only (RUO).

1- Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA (1998). “Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice”. Endocr. Rev. 19 (3): 225–68.

2- Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffé M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA (1997). “A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia”. Science 278 (5341): 1309–12.

3- Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O’Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC (2005). “The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2”. Cancer Res. 65 (7): 2662–7.

4- Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005). “A gain-of-function mutation of JAK2 in myeloproliferative disorders”. N. Engl. J. Med. 352 (17): 1779–90